MA45397A - Composés, compositions et procédés pour augmenter l'activité du cftr - Google Patents
Composés, compositions et procédés pour augmenter l'activité du cftrInfo
- Publication number
- MA45397A MA45397A MA045397A MA45397A MA45397A MA 45397 A MA45397 A MA 45397A MA 045397 A MA045397 A MA 045397A MA 45397 A MA45397 A MA 45397A MA 45397 A MA45397 A MA 45397A
- Authority
- MA
- Morocco
- Prior art keywords
- cftr
- compositions
- activity
- compounds
- processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352672P | 2016-06-21 | 2016-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45397A true MA45397A (fr) | 2019-04-24 |
Family
ID=59337861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045397A MA45397A (fr) | 2016-06-21 | 2017-06-21 | Composés, compositions et procédés pour augmenter l'activité du cftr |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10899751B2 (fr) |
| EP (1) | EP3472156B1 (fr) |
| AU (2) | AU2017280206A1 (fr) |
| ES (1) | ES2954658T3 (fr) |
| MA (1) | MA45397A (fr) |
| WO (1) | WO2017223188A1 (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI735416B (zh) | 2014-10-06 | 2021-08-11 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| MA42488A (fr) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CA3000483C (fr) | 2015-10-06 | 2024-02-13 | Proteostasis Therapeutics, Inc. | Composes, compositions et methodes permettant de moduler le cftr |
| BR112018070747B1 (pt) | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
| MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| SI3519401T1 (sl) | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
| CN110267948B (zh) | 2016-12-09 | 2023-12-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法 |
| CN110325562A (zh) * | 2017-03-29 | 2019-10-11 | 住友精化株式会社 | 吸水性树脂 |
| AU2018279646B2 (en) | 2017-06-08 | 2023-04-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| MA49631A (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019156946A2 (fr) * | 2018-02-06 | 2019-08-15 | Research Institute At Nationwide Children's Hospital | Compositions et procédés pour améliorer la fonction cftr dans des cellules affectées par la fibrose kystique |
| AU2019222758B2 (en) | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
| US20210139514A1 (en) | 2018-04-05 | 2021-05-13 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP3774825A1 (fr) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| WO2020006269A1 (fr) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Composés améliorant l'activité du protéasome |
| CA3116015A1 (fr) | 2018-10-30 | 2020-05-07 | University Of Florida Research Foundation, Incorporated | Compositions d'acides amines et methodes de traitement de la fibrose kystique |
| WO2020115231A1 (fr) * | 2018-12-06 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions destinées au traitement des voies respiratoires atteintes de mucoviscidose |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| CA3150162A1 (fr) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Formes cristallines de modulateurs de cftr |
| WO2021041997A1 (fr) | 2019-08-28 | 2021-03-04 | The Regents Of The University Of California | Co-potentialisateurs pour thérapie de la fibrose kystique provoquée par des mutants cftr à fonction minimale |
| EP4100023A4 (fr) * | 2020-02-07 | 2024-03-13 | University of South Florida | Inhibition de l'oligomérisation de la bêta-arrestine en tauopathie |
| IL300413A (en) | 2020-08-13 | 2023-04-01 | Vertex Pharma | Crystal forms of CFTR modulators |
| EP3970718A1 (fr) * | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | Nouvelle utilisation médicale des modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique (cftr) |
| EP4225762A1 (fr) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
| AU2021397294A1 (en) | 2020-12-10 | 2023-07-06 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336264A (en) | 1980-06-19 | 1982-06-22 | Eli Lilly And Company | 1-Benzoyl-3-(isoxazolyl or benzisoxazolyl)-ureas and insecticidal use thereof |
| DE3812225A1 (de) | 1988-04-13 | 1989-10-26 | Basf Ag | Isoxazol(isothiazol)-5-carbonsaeureamide |
| BR9606546A (pt) | 1995-08-02 | 1998-07-14 | Uriach & Cia Sa J | Novas carboxamidas com atividade fungicida |
| EP0761654B1 (fr) | 1995-08-24 | 2003-06-18 | Basf Aktiengesellschaft | Dérivés d'isoxazole- et d'isothiazole-5-carboxamide, leur préparation et leur utilisation comme herbicides |
| DE69903992T2 (de) | 1998-04-15 | 2003-08-21 | Pfizer Products Inc., Groton | Heterocyclische Carboxamide |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| EP1501514B1 (fr) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Modulateurs de proteine-kinases et leurs methodes d'utilisation |
| MXPA06004005A (es) | 2003-10-08 | 2006-06-28 | Vertex Pharma | Moduladores de transportadores con casete de union con atp. |
| JP4869072B2 (ja) | 2003-11-14 | 2012-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール |
| WO2005077345A1 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Composes pour le traitement de la maladie du reflux gastro-oesophagien |
| WO2005077373A2 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Nouveau traitement du reflux gastro-oesophagien pathologique ii |
| EP1742627A4 (fr) | 2004-05-06 | 2009-08-26 | Plexxikon Inc | Inhibiteurs de pde4b et leurs utulisations |
| SE0401969D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidine derivatives |
| US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| DE602006018301D1 (de) | 2005-06-22 | 2010-12-30 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| WO2007075896A2 (fr) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Inhibiteurs de cytokine heterocycliques |
| KR101394245B1 (ko) | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| WO2007086584A1 (fr) | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | NOUVEL INHIBITEUR DE FabK ET DE FabI/K |
| TW200815351A (en) | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| WO2008046072A2 (fr) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Inducteurs chimiques de la neurogénèse |
| WO2008051757A1 (fr) | 2006-10-20 | 2008-05-02 | Irm Llc | Compositions et procédés de modulation de récepteurs de c-kit et de facteur de croissance dérivé de plaquettes (pdgfr) |
| WO2008070739A1 (fr) | 2006-12-06 | 2008-06-12 | Cytokinetics, Inc. | Activateurs de ksp |
| CN101778845B (zh) | 2007-06-29 | 2014-06-25 | 爱思开生物制药株式会社 | 用于预防和治疗再狭窄的包含异噁唑衍生物的药物组合物 |
| WO2009011850A2 (fr) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Nouveaux composés thérapeutiques |
| JP2011511756A (ja) | 2007-08-02 | 2011-04-14 | ナームローゼ・フエンノートチヤツプ・オルガノン | Ｔｒｐｖ１モジュレータとしての５−フェニル−イソオキサゾール−３−カルボキサミド誘導体 |
| WO2009086303A2 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
| US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US20090318429A1 (en) | 2008-04-28 | 2009-12-24 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives |
| AU2010211114A1 (en) | 2009-02-04 | 2011-06-30 | Msd Oss B.V. | Isoxazole-5-carboxamide derivatives |
| MX2011009414A (es) | 2009-03-11 | 2011-10-19 | Kyorin Seiyaku Kk | 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3. |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| IN2012DN00352A (fr) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
| WO2011008931A2 (fr) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| US8569899B2 (en) | 2009-12-30 | 2013-10-29 | Stmicroelectronics, Inc. | Device and method for alignment of vertically stacked wafers and die |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| JP5996532B2 (ja) | 2010-07-15 | 2016-09-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 有害生物防除剤としての新規複素環式化合物 |
| SG193002A1 (en) | 2011-03-10 | 2013-09-30 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivative |
| CA2736441A1 (fr) | 2011-04-06 | 2012-10-06 | The Regents Of The University Of California | Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique |
| JP6063455B2 (ja) | 2011-05-18 | 2017-01-18 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化されたイバカフトルの誘導体 |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038386A1 (fr) | 2011-09-16 | 2013-03-21 | Novartis Ag | Composés hétérocycliques destinés au traitement de la mucosviscidose |
| US8623860B2 (en) | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
| JP6138834B2 (ja) | 2012-02-16 | 2017-05-31 | ダウ アグロサイエンシィズ エルエルシー | スルフィルイミン化合物の製造方法 |
| UA110436C2 (en) | 2012-03-06 | 2015-12-25 | Zoetis Llc | Antibacterial phenol compounds |
| WO2013146970A1 (fr) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | Nouveau dérivé de quinoléine |
| WO2014045283A1 (fr) | 2012-09-24 | 2014-03-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Restauration de la fonction cftr par modulation de l'épissage |
| AU2013348018A1 (en) | 2012-11-20 | 2015-06-04 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
| EP2922853A4 (fr) | 2012-11-20 | 2016-11-23 | Discoverybiomed Inc | Correcteurs de cftr bicycliques et tricycliques à petites molécules |
| EP2968285A4 (fr) | 2013-03-13 | 2016-12-21 | Flatley Discovery Lab | Composés et procédés pour le traitement de fibrose kystique |
| EP2968323A4 (fr) | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | Composés de pyridazinone et procédés pour le traitement de fibrose kystique |
| US9815825B2 (en) | 2013-03-15 | 2017-11-14 | Discoverybiomed, Inc. | Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders |
| EP2968987A4 (fr) | 2013-03-15 | 2017-04-26 | Vertex Pharmaceuticals Inc. | Correcteurs agissant par l'intermédiaire de msd1 de la protéine cftr |
| US20160074374A1 (en) | 2013-04-26 | 2016-03-17 | Vertex Pharmaceuticals Incorporated | Correctors acting through msd1 of cftr protein |
| EP2994463B1 (fr) | 2013-05-07 | 2017-10-25 | Galapagos NV | Nouveaux composés et leurs compositions pharmaceutiques pour le traitement de la mucoviscidose |
| WO2014181287A1 (fr) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Composés hétérocyclyliques et leurs utilisations |
| WO2014210159A1 (fr) | 2013-06-26 | 2014-12-31 | Proteostasis Therapeutics, Inc. | Procédés de modulation de l'activité de cftr |
| US9920073B2 (en) | 2013-10-04 | 2018-03-20 | Drexel University | Compositions useful for inhibiting HIV-1 infection and methods using same |
| CA2942386A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
| WO2015138934A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité cftr |
| CA2952862A1 (fr) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
| WO2016054560A1 (fr) * | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Composés isoxazoles et procédés pour le traitement de la fibrose kystique |
| CA2971850A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derives d'amides 5-phenyl- ou 5-heteroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique |
| WO2016105468A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Dérivés de 3-hétéroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| MA42488A (fr) | 2015-07-24 | 2018-05-30 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| WO2017040606A1 (fr) | 2015-08-31 | 2017-03-09 | Proteostasis Therapeutics, Inc. | Dérivés d'isoxazole destinés à être utilisés dans le traitement de maladies et de troubles pulmonaires |
| CA3000483C (fr) | 2015-10-06 | 2024-02-13 | Proteostasis Therapeutics, Inc. | Composes, compositions et methodes permettant de moduler le cftr |
| MA44126A (fr) | 2015-12-22 | 2018-10-31 | Proteostasis Therapeutics Inc | Méthodes de traitement de maladies et troubles pulmonaires |
| BR112018070747B1 (pt) | 2016-04-07 | 2024-01-09 | Proteostasis Therapeutics, Inc | Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos |
| CA3023512A1 (fr) | 2016-05-09 | 2017-11-16 | Proteostasis Therapeutics, Inc. | Procedes d'identification de modulateurs du cftr |
| MA45397A (fr) | 2016-06-21 | 2019-04-24 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
-
2017
- 2017-06-21 MA MA045397A patent/MA45397A/fr unknown
- 2017-06-21 WO PCT/US2017/038521 patent/WO2017223188A1/fr not_active Ceased
- 2017-06-21 AU AU2017280206A patent/AU2017280206A1/en not_active Abandoned
- 2017-06-21 EP EP17739769.2A patent/EP3472156B1/fr active Active
- 2017-06-21 ES ES17739769T patent/ES2954658T3/es active Active
- 2017-06-21 US US16/311,397 patent/US10899751B2/en active Active
-
2021
- 2021-08-10 AU AU2021215136A patent/AU2021215136B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017223188A1 (fr) | 2017-12-28 |
| AU2017280206A1 (en) | 2019-01-17 |
| AU2021215136B2 (en) | 2023-07-27 |
| US10899751B2 (en) | 2021-01-26 |
| US20200010461A1 (en) | 2020-01-09 |
| EP3472156A1 (fr) | 2019-04-24 |
| AU2021215136A1 (en) | 2021-09-02 |
| ES2954658T3 (es) | 2023-11-23 |
| EP3472156B1 (fr) | 2023-06-07 |
| CA3028966A1 (fr) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45397A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| MA41253A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| MA42488A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| MA49061A (fr) | Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr | |
| EP3442488A4 (fr) | Compositions pour l'application topique de composés | |
| IL283042A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| EP3359164A4 (fr) | Composés et procédés pour moduler l'expression de l'angiotensinogène | |
| EP3370715A4 (fr) | Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci | |
| EP3353309A4 (fr) | Compositions et méthodes pour l'édition génomique | |
| EP3386550A4 (fr) | Procédés et compositions pour la fabrication et l'utilisation d'acides nucléiques de guidage | |
| EP3431075A4 (fr) | Forme galénique d'édaravone | |
| EP3267995A4 (fr) | Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose | |
| EP3519572A4 (fr) | Composés et procédés pour réduire l'expression de tau | |
| EP3443094A4 (fr) | Procédés de réduction de l'expression de c9orf72 | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| EP3645013A4 (fr) | Compositions et procédés pour inhiber l'expression de hmgb1 | |
| EP3476478A4 (fr) | Composition pour l'élimination de composés soufrés | |
| EP3250230A4 (fr) | Modulateurs d'activité du complément | |
| EP3412344A4 (fr) | Composition d'agent extincteur | |
| EP3397288A4 (fr) | Méthodes pour diminuer l'expression de l'ataxine-2 | |
| PL3487491T3 (pl) | Kompozycje do zwiększenia aktywności mózgu | |
| EP3530722A4 (fr) | Composition d'agent nettoyant | |
| EP3538219A4 (fr) | Compositions topiques destinées au traitement de l'acné | |
| EP3261631A4 (fr) | Inhibition de l'activité d'olig2 | |
| EP3362578A4 (fr) | Méthodes d'évaluation génomique du bétail |